Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy

Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy

Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitides associated with antineutrophil cytoplasm antibodies (AAV) in both newly diagnosed and relapsing patients. However, the role of RTX in the management of the most severe ca...

Full description

Bibliographic Details
Main Authors: Dario Roccatello, Savino Sciascia, Stefano Murgia, Giacomo Quattrocchio, Michela Ferro, Emanuele De Simone, Carla Naretto, Antonella Barreca, Andrea Sammartino, Daniela Rossi, Roberta Fenoglio
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Immunology
Subjects:
ANCA-associated vasculitis
rituximab
glomerulonephritis
vasculitis
polyangiitis and granulomatosis
polyangiitis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.777134/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.777134/full

Similar Items